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Abstract
Background: Smoothelin-like 1 (SMTNL1, also known as CHASM) plays a role in promoting relaxation as well as
adaptive responses to exercise, pregnancy and sexual development in smooth and skeletal muscle. Investigations
of Smtnl1 transcriptional regulation are still lacking. Thus, in this study, we identify and characterize key regulatory
elements of the mouse Smtnl1 gene.
Results: We mapped the key regulatory elements of the Smtnl1 promoter region: the transcriptional start site (TSS)
lays -44 bp from the translational start codon and a TATA-box motif at -75 bp was conserved amongst all
mammalian Smtnl1 promoters investigated. The Smtnl1 proximal promoter enhances expression up to 8-fold in
smooth muscle cells and a second activating region lays 500 bp further upstream. Two repressing motifs were
present (-118 to -218 bp and -1637 to -1869 bp). The proximal promoter is highly conserved in mammals and
contains a mirror repeat sequence. In silico analysis suggests many transcription factors (notably MyoD) could
potentially bind within the Smtnl1 proximal promoter sequence.
Conclusion: Smtnl1 transcript was identified in all smooth muscle tissues examined to date, albeit at much lower
levels than found in skeletal muscle. It is unlikely that multiple SMTNL1 isoforms exist since a single Smtnl1
transcription start site was identified in both skeletal and intestinal smooth muscle. Promoter studies suggest
restrictive control of Smtnl1 expression in non-muscle cells.
Background
The smoothelin-like 1 (SMTNL1 [Swiss-Prot: Q99LM3])
protein was discovered as a novel protein phosphory-
lated in response to cGMP stimulation of ileal smooth
muscle tissue [1]. The protein contains a calponin
homology domain at its carboxy-terminus, thus it was
originally termed the calponin homology-associated
smooth muscle protein (CHASM). Experiments com-
pleted in situ with isolated smooth muscle tissues sug-
gest a physiological role for SMTNL1 in promoting the
relaxant actions of PKA/PKG [1,2], and studies with
Smtnl1 genetic knock-out mice link SMTNL1 with
adaptive responses to exercise in both smooth and ske-
letal muscle [3]. More recent studies have provided indi-
cations that SMTNL1 also governs smooth and skeletal
muscle adaptations during sexual development and
pregnancy [4]. Although less well studied at the
molecular level, current data suggests SMTNL1 plays an
important regulatory role in smooth muscle contraction
and development. The protein is known to interact with
t r o p o m y o s i n[ 5 ]a n dw i t ha p o - c a l m o d u l i ni naC a
2+
dependent manner [6], to inhibit myosin phosphatase
activity [2,3] and to regulate the expression of the myo-
sin phosphatase targeting subunit (MYPT1) [4].
As its name suggests, SMTNL1 is closely related to the
smoothelin family of proteins (SMTN) that are used as
markers for contractile smooth muscle cell differentiation
[ 7 , 8 ] .T h es p e c i f i cb i o l o g i c a lr o l eo ft h et w oS M T Ni s o -
forms, A (short isoform, predominantly visceral expres-
sion) and B (long isoform, predominantly vascular
expression), remains poorly defined; however, the analysis
of mice lacking SMTN-A or -B has revealed critical roles
for each of the proteins in intestinal and vascular smooth
muscle performance, respectively [9,10]. Interestingly, the
SMTN-A and SMTN-B isoforms are expressed from alter-
native promoters, with the intragenic promoter of SMTN-
A residing within exon 10 of the Smtn gene [11]. Thus,
one Smtn gene gives rise to both SMTN-A and SMTN-B
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Smtn promoter is controlled by serum response factor
(SRF) and myocardin [12]. SRF and myocardin play critical
roles in the expression and regulation of growth-responsive
genes as well as the expression of virtually all smooth
muscle specific genes, such as calponin, myosin heavy
chain, a-actin and SM-22 [13,14]. Previous analyses of
various smooth muscle and general tissues by immuno-
histochemistry and Western blotting have revealed strong
expression of SMTNL1 in MHC-2A skeletal muscle fibers,
moderate expression in smooth muscle tissues (e.g., blad-
der, ileum, uterus and aorta) and no expression in MHC-I/
b cardiac muscle [3]. Given that SMTNL1 is expressed in
multiple muscle types, it was expected that Smtnl1
transcriptional regulation might differ from the other
smoothelin family members.
To date, the contribution of the SMTNL1 protein in
smooth muscle contraction has been examined in vitro
and in vivo [1-6], but investigations of its gene and tran-
scriptional regulation are still lacking. Thus, in this
study, we identify and characterize key regulatory ele-
ments of the promoter region in the mouse Smtnl1
gene. This region contains a TSS mapped to a location
119 bp downstream of the NCBI-predicted site. Our
data demonstrate that a proximal promoter region is
located within 118 bp of the TSS site and provide mole-
cular insights into the regulation of the Smtnl1 gene.
Results and Discussion
PCR analysis of Smtnl1 transcript
We first examined the pattern of Smtnl1 expression in
skeletal muscle and representative smooth muscle tis-
sues with RT-PCR. As shown in Figure 1A, the Smtnl1
transcript is expressed at very low levels. Smtnl1 expres-
sion in skeletal and aortic smooth muscle tissues was
detectable following 35-cycles of amplification; however,
transcript was not detected by RT-PCR in other smooth
muscle beds. To increase the sensitivity of detection, we
then performed nested PCR reactions on the primary
products. This step also increased the specificity of the
PCR reaction and permitted qualitative verification of
Smtnl1 expression. We detected Smtnl1 expression by
nested PCR in the muscle tissues selected for analysis.
The nested-PCR amplicons were sequenced and align
100% to the Smtnl1 sequence. Due to its low abundance,
we were unable to accurately assess the expression levels
in different tissues with qPCR techniques.
We also investigated the expression of mRNA encod-
ing SMTNL1 transcripts in various human tissues with
Northern blot analysis. For this study, we used a 1.0-kb
5’-probe based on mouse Smtnl1 and moderate strin-
gency washes. The probe was generated to include the
sequence encoding the N-terminal 273 amino acid resi-
dues of SMTNL1 in order to avoid cross-reactivity with
other transcripts that possess sequence encoding a cal-
ponin homology (CH)-domain, such as the smoothelins.
A single transcript of ~2.1-kb was detected in skeletal
muscle (Figure 1B) and correlated with the predicted
mRNA size of 1.8-kb. No other mRNA species were
identified, implying that a single Smtnl1 transcript exists
in skeletal muscle. Although we obtained a strong signal
for Smtnl1 mRNA in skeletal muscle, northern signals
were not detected in tissues with high vascular content
such as brain and kidney or in tissues with high smooth
muscle content (e.g., placenta, small intestine or colon).
As seen from our nested-PCR results, a number of
smooth muscle tissues do possess Smtnl1 mRNA, but at
much lower levels than skeletal muscle which might
account for the inability to detect expression by North-
ern blotting. These data agree with protein distributions
as determined previously by Western blotting [3]. Inter-
estingly, recent studies have revealed that exercise- and
Figure 1 Expression profile of Smtnl1 in various mouse and
human tissues.I n(A), an RT-PCR reaction (denoted 1; expected
size, 440 bp) was performed on total RNA extracted from mouse
skeletal muscle (SKM) and smooth muscle dissected from aorta
(AO), ileum (ILM), colon (COL) and urinary bladder (BL). The RT-PCR
was followed by nested PCR (denoted N; expected size, 313 bp) to
increase the specificity and sensitivity of the detection. RT-PCR
reactions of GAPDH (denoted G; expected size, 240 bp) was
performed to control for the integrity of the extracted mRNA.
Results are representative of replicate PCR reactions completed on
cDNA synthesized from two separate mice. In (B), Northern blot
analysis of Smtnl1 expression in human tissues was completed on a
Clontech multi-tissue membrane with 1 μg polyA+ RNA loaded per
lane. The membrane was hybridized overnight with a
32P-labeled
Smtnl1 cDNA probe (1 - 1038 bp) and exposed to X-ray film. The
major human Smtnl1 transcript of 2.1-kb is indicated by the
arrowhead.
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were linked to functional adaptations in skeletal and
smooth muscle contractile performances. Given these
previous findings, it will be important to generate an
accurate tool to quantitatively analyze Smtnl1 transcript
levels in human tissues and/or mouse models of disease.
Smtnl1 transcription start site mapping
The murine Smtnl1 gene [GenBank: 68678] is located
on chromosome 2, E1 and spans 11.48-kb with 8 exons.
The mRNA sequence [GenBank: NM_024230] has been
annotated using bioinformatic and curatorial analyses in
the NCBI Refseq database. A thymidine residue at -162
bp from the translational start site (AUG) within the
Smtnl1 mRNA was assigned as the provisional transcrip-
tional start site (TSS). This positions the ATG at the
start of exon 2 while exon 1 (162 nt) is not translated.
To verify the location of the TSS in the Smtnl1 gene,
we performed 5’-RACE experiments on murine smooth
and skeletal total RNA. Three reverse, gene-specific pri-
mers were designed for the PCR step that follows cDNA
synthesis in the 5’-RACE process (see Table 1). Primer
GSP3 and GSP 2 anneal just downstream of the TSS
and upstream of the AUG (expected PCR product 63 bp
and 176 bp, respectively). Primer GSP1 anneals just
upstream and outside of the CH domain in exon 8
(expected PCR product 1479 bp).
The 5’-RACE PCR on smooth muscle (Figure 2A) and
skeletal muscle (Figure 2B) total RNA produced low (<
250 bp) molecular weight cross-dimer products between
the GSP and 5’-RACE UPM primers (as verified by
sequencing). When skeletal muscle mRNA was used as
template together with primer GSP1, a faint band was
visible at approximately 1.5-kb that was close to the
expected product size (Figure 2B). To increase specifi-
city and sensitivity, a second round of PCR was per-
formed using nested primers on the products from the
5’-RACE PCR. The expected amplicon sizes with the
NCBI-predicted TSS were 63 bp for NGSP1 and 823 bp
for NGSP2. A strong band of approximately 700 bp was
observed for nested PCR reactions completed on both
smooth and skeletal muscle GSP1 PCR products (Figure
2A &2B), somewhat smaller than the expected 823 bp
product for the NGSP2 primer. Sequence analysis
revealed a partial alignment of the 823 bp NGSP2 pro-
duct with Smtnl1, starting within exon 1.
The 5’ end of the product was 119 bp shorter than
expected from the NCBI-predicted TSS. To further vali-
date the TSS identified with 5’-RACE, ribonuclease pro-
tection assays (RPA) were performed. A ssRNA
riboprobe (511 nt) was generated to span both the NCBI-
predicted and 5’-RACE-derived TSS. A protected frag-
ment of 369 bp was expected for the NCBI-predicted
TSS whereas a 231 bp fragment was expected for the
newly derived TSS. As shown in Figure 2C, RPA was
completed with smooth and skeletal muscle mRNA and
biotin-18-UTP-labeled riboprobe. As expected, the full-
length probe was detected near the 500 bp marker.
A protected fragment slightly larger than 200 bp was
detected in the RPA with the addition of skeletal muscle
mRNA. This result further confirms the TSS location to
be different from that annotated in the NCBI database,
occurring less than 50 nt upstream of the translational
start codon. No protected fragment was detected when
yeast RNA (control) or smooth muscle RNA was used in
the RPA. The latter result was likely due to lack of sensi-
tivity of the RPA conditions for low abundance mRNAs.
Analysis of the sequence located upstream of the start
codon (ATG) in murine Smtnl1 indicated the presence
of an initiator (Inr) sequence and a TATA box (Figure
2D). Therefore, our experimentally mapped Smtnl1 TSS
corresponded to a thymidine within the Inr sequence
(CTAGAAC, where the T was the first transcribed
nucleotide) and was located 44 nt upstream of the trans-
lational start codon. The putative TATA box sequence
was identified at -23 to -31 nt upstream of the new TSS.
Further sequence analysis showed that the Inr and
TATA sequences of Smtnl1 are conserved within a vari-
ety of mammalian Smtnl1 genes.
The expression profile of Smtnl1 differs from the other
smoothelin (Smtn) family members that are exclusively
expressed in differentiated smooth muscle cells. The
Smtnl1 promoter was expected to be different since the
smoothelins are not expressed in any tissue but smooth
muscle cells. Indeed, the promoter sequences of smooth-
elins and Smtnl1 do not bear any resemblance to each
other, despite some similarities in the protein-coding
region (mainly within the C-terminal calponin homology
domain). The SMTN-A and SMTN-B isoforms of the
Smtn gene are generated by alternative transcriptional
start sites [11] that provide selective expression of each
isoform in visceral and vascular smooth muscle beds,
respectively. Moreover, alternative splicing produces
three different C-terminal variants of each SMTN iso-
f o r m[ 1 5 ] .I ti su n l i k e l yt h a tm u l t i p l eS M T N L 1i s o f o r m s
exist since a single Smtnl1 TSS was identified from both
skeletal and intestinal smooth muscle total RNA with
sequencing of several 5’-RACE clones. All sequences
commenced at a thymine located 44 nt upstream of the
translational start site (ATG). However, we have not yet
completed 5’-RACE on Smtnl1 transcripts isolated from
vascular tissue. Furthermore, we cannot exclude the pre-
sence of multiple C-terminal splice variants since we did
not complete 3’-RACE analysis.
SMTNL1 promoter reporter assay
To locate cis-elements in the core promoter region that
modulate expression of Smtnl1, we constructed deletion
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tored Gaussia luciferase reporter activities in rat aortic
A7r5 smooth muscle cells. Promoter sequences were
generated spanning up to 2.7-kb upstream of the newly
derived Smtnl1 TSS and cloned into a promoterless
pGLuc luciferase vector. Figure 3A shows the relative
luciferase activity using progressively shorter promoter
constructs. A 3.5-fold induction was observed for the
upstream region spanning +100 to -2759. Deletion of
the region from -1637 to -1869 increased the luciferase
induction to 8.5-fold while removal of the sequence
from -468 to -1637 elicited no further effect. The mini-
mal sequence establishing the proximal promoter (0 to
-118) provided a 7-fold luciferase induction. Finally, the
first 100 bases downstream of the new TSS had no
activity. These data reveal two regions of promoter
Table 1 PCR primers used in the analysis of Smtnl1
RT-PCR & nested PCR
mSmtnl1-F1 AAGAAGGATCGAGCACCAGAAC
mSmtnl1-R1 ACACACTTGGAATCGGGCAC
mSmtnl1-nested-F1 GGAAGGCCATCATGGACAAATTT
mSmtnl1-nested-R1 GCACAGTCGGCTAGTTTCTCTG
5’-RACE
5’-CDS dT25VN (N = A, C, G, or T; V = A, G, or C)
SMART II A AAGCAGTGGTATCAACGCAGAGTACGCGGG
UPM 5:1 mixture of (1): (2)
(1) CTAATACGACTCACTATAGCAAGCAGTGGTATCAACGCAGAGT
(2) CTAATACGACTCACTATAGC
NUPM AAGCAGTGGTATCAACGCAGAGT
GSP1 CCACCTCCAGCAGCTGGGCACAGTCGGCTAG
GSP2 GCCTCGTTCTAGCCGAGCTGCCTCACTCTCCAT
GSP3 CACCCCACCTTCAAGAGGCCCGGGCTTCG
NGSP1 CACCCCACCTTCAAGAGGC
NGSP2 CCAACTCCTTTGTGTCACTTCCG
RPA
RPA2 TAATACGACTCACTATAGGGCTGATCAGATGCTAGGTACACTT
GCTTCCACCACCCCTTGCTTCCACC
T7 promoter TAATACGACTCACTATAGGG
RPA-NCS GAGAGGGACGCAGCAGCGTG
RPA-NCA GGTTCTGCCTGCAGCTCGG
RPA-M1-2S TAGAACGAGGCAAGAGCTCC
RPA-M1-2A GTTCTGCCCAATCTGAAGGC
RPA-FR1 GCCACCTGTCAGATCTTCGG
RPA-RT7 TAATACGACTCACTATAGGGCTGATCAGATGCTAGGTACAG
TTCTGCCCAATCTGAAG
Promoter Truncations
+100 bp LUC R1 GTGGGATCCGTGAAAGGTAAGAATAGG
0 bp LUC F1 CTAGCCTTCTAGAACGAGGCAAGAGCTCC
-118 bp LUC F2 CTAGAATTCCTTCCCGAAGCCCGGGC
-218 bp LUC F3 CTCGAATTCGCAGCGTGATTGAAAGATG
-468 bp LUC F4 CTAGAATTCCCCCTCAGCAGCTACTTTG
-767 bp LUC F5 CTCGAATTCCGTTGGGAACTGGGAATTCCG
-1350 bp LUC F6 CTAGAATTCGACAAAGCTTGGGGTCTATATC
-1637 bp LUC F7 CTAGAATTCCTCTTAACCTCCAAGACATC
-1869 bp LUC F8 CTAGAATTCCTCTTAACCTCCAAGACATC
-2368 bp LUC F9 CTAGAATTCCAAAGTCCTATTGCTTGCACC
-2759 bp LUC F10 GCTGAATTCGAATTATCTCATGGACTTGCCTAGAG
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-468 and 0 to -118. Furthermore, two inhibitory ele-
ments were also defined, -1637 to -1869 and -118 to
-218. These results demonstrate that the first 118 bp
upstream of the Smtnl1 TSS could significantly enhance
luciferase production, suggesting that the core promoter
was located in this region. Importantly, the region of the
core promoter did not include the TSS previously anno-
tated in NCBI. Our data confirms that the region imme-
diately upstream of the NCBI-annotated TSS could not
enhance expression, which further verifies our newly
identified TSS downstream of the NCBI-annotated TSS.
We further investigated the sequence of the first 118 bp
upstream of the TSS for possible promoter elements.
A TTAAA motif, 31 nt upstream of the TSS, was 100%
conserved amongst all the mammalian Smtnl1 promo-
ters investigated and is predicted to serve as a TATA-
box. We were unable to identify a CAAT element.
The promoter region just upstream and including the
TSS is highly conserved in mammals, emphasizing its
importance. The TSS of some mammals is not anno-
tated in this region, and this might be due to difficulties
in identifying 5’-UTRs within the corresponding ESTs.
Further corroborating this possibility was the distance
between the TSS (equivalent to murine exon 1) and the
translational start-site (ATG) in murine exon 2. In all
mammals, this distance was similarly expansive (e.g.,
3400 bp (dog) to 5200 bp (cow)). We propose that all
Figure 2 Identification of the transcription start site of Smtnl1 by rapid amplification of cDNA 5’-ends (5’-RACE) and ribonuclease
protection assay (RPA).5 ’-RACE reactions were performed on cDNA synthesized from smooth (A) or skeletal (B) muscle mRNA with primers
specific for Smtnl1. Representative ethidium bromide-stained agarose gels of PCR products are shown. A 5’-RACE CDS primer (Stratagene) and
three Smtnl1 gene specific primers (GSPs) were used with expected product sizes: GSP1 (1479 bp), GSP2 (176 bp) and GSP3 (83 bp). The 5’-RACE
product from each reaction was used as template in a subsequent nested PCR reaction. The expected sizes of the nested PCR products were:
NGSP1 (63 bp) and NGSP2 (823 bp). The arrowhead in (B) indicates the PCR product visible during the primary amplification when skeletal
muscle cDNA was used as template for 5’-RACE with GSP1. The DNA ladder markers are indicated on the left.I n(C), ribonuclease protection
assay (RPA) analysis was performed on 10 μg of total RNA from smooth (SM) and skeletal (SKM) muscle. A biotin-labeled Smtnl1 riboprobe was
generated to span -112 bp to the TSS, joined to exon 1 and exon 2 from the Smtnl1 mRNA, up to + 319 bp. Total RNA from S. cerevisiae (10 μg)
was used instead of muscle RNA as a negative control. The band appearing with skeletal muscle mRNA is marked by an arrow. The DNA ladder
markers are indicated on the left.I n(D), the promoter region, eight exons (E1-E8) and 7 intronic DNA sections are shown for the mouse Smtnl1
gene. The positions of the start codon (ATG), transcriptional start site (TSS) defined by 5’-RACE, the TATA box and initiator sequence (Inr) are also
indicated. The nucleotides identified by sequencing the cDNA clones (n = 5) obtained from 5’-RACE are underlined.
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of the conserved region, similar to the murine promoter.
This would add an additional 5’-UTR exon 1 to human,
rat and horse Smtnl1.
We also investigated whether the pattern of luciferase
inductions observed with the Smtnl1 promoter
sequences resulted from a specific set of transcription
factors unique to A7r5 smooth muscle cells. For this,
the activities of three Smtnl1 promoter constructs were
also assessed in HEK 293 (human embryonic kidney)
and Rat-1 (rat fibroblast) cell lines (Figure 3B). The
same pattern of luciferase induction was seen in these
cell lines; however, the maximal activation measured
was only 3-fold, a significant reduction when compared
to the maximal activity found in A7r5 smooth muscle
cells. The identified cis-acting promoter spanned at least
1869 bp and could up- or down-regulate expression in
A7r5, Rat-1 and HEK 293 cells, depending on which
region was present. However, the much higher maxi-
mum activation in smooth muscle cells compared to
fibroblast and kidney cells suggests restrictive control of
Smtnl1 expression in non-muscle cells and emphasizes
Figure 3 Identification of enhancer and repressor regions within the Smtnl1 promoter.I n(A), various deletions (left)o ft h eSmtnl1
promoter region spanning +100 bp to -2759 bp were used to drive expression of the Gaussia luciferase gene. The positions were numbered from
the transcriptional start site (TSS) identified by 5’-RACE in this study. A7r5 cells were transiently co-transfected with the pGLuc reporter and the
constitutively active b-galactosidase (b-gal) reporter vector, pbAct-b-gal for normalization. After 48 hr, the media and cell lysates were assayed for
luciferase and b-gal activities, respectively. Luciferase activity was normalised to b-gal activity and expressed as fold-increase (right) relative to the
activity of the empty pGLuc vector. All values are mean ± S.E.M. (n = 5-8). *- significantly different from +100 - 0 bp promoter region; #- significantly
different from 0 to -118 bp promoter region. Statistical analysis was completed with ANOVA and Student-Neumann-Keuls post-hoc analysis, p <
0.05. Additional studies (B) also examined luciferase expression in Rat 1 fibroblast and human embryonic kidney (HEK 293) cell lines 48 hr after
transient co-transfection with the pGLuc reporter vector and pbAct-b-gal for normalization. All values are mean ± S.E.M. (n = 3).
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tractile function.
In silico analysis of putative transcription factor binding
sites within Smtnl1
A comparison of TSS sites in various mammalian
Smtnl1 genes was undertaken, and BLAST searches
revealed that exon 1 is not translated and the murine
ATG start codon is located at the beginning of exon 2.
In the case of some mammals (i.e., human, rat and
horse), the Smtnl1 gene starts with the ATG in exon 1
and is analogous to murine exon 2. Further investigation
of these Smtnl1 variants revealed the location of a geno-
mic region that has not been annotated. This region lays
several thousand bases upstream with high similarity to
the murine exon 1. Comparison of various mammalian
SMTNL1 protein sequences revealed the highest conser-
vation at the N- and C-termini (aa 1 - 17 as well as aa
209 - 459). Thus, it is not surprising that, based on pro-
tein sequence and gene sequence alignment, the exon
including the start codon was annotated in all mammals
while the upstream exon 1 was sometimes not annotated.
In agreement with the observation that exon 1 is often
located far upstream of exon 2, there is approximately
3000 to 4000 bp separating the conserved region corre-
sponding to the mouse 5’-UTR and the ATG start codon
of Smtnl1 from various mammalian species (Figure 4A).
Based on these findings, it is reasonable to predict that
the human Smtnl1 TSS lies upstream of the region
homolog to murine smtnl1 exon 1, even though it
remains to be annotated. Indeed, the region just
upstream of the murine TSS is highly conserved in mam-
mals, with > 75% percent identity (Figure 4A).
The highest conservation in the murine Smtnl1 5’-
UTR sequence was located between -80 bp and -220 bp
relative to the newly derived TSS, suggesting functional
importance. Indeed, the region corresponds in part to
the strongly activating construct determined with the
luciferase reporter assay (i.e., +100 to -118). We
searched for transcription factor binding sites (TFBS) in
this region using the PATCH program that utilizes the
TRANSFAC
® database of cis-acting transcription factors
[16,17]. Possible mammalian TFBSs in this region include
AP2a,S F - 1 ,R X R a,S P 1 ,E Ra n dc - m y ca m o n g s to t h e r s
(Figure 4B). Intriguingly, this region of the Smtnl1 pro-
moter also possesses a putative TFBS for MyoD
Figure 4 In silico analysis of putative transcription factor binding sites within the mouse Smtnl1 promoter region.I n(A), a comparative
analysis of mammalian Smtnl1 promoter regions was completed. The promoter sequences were aligned using CLUSTALW and Genedoc. The
sequence similarities are: black, 100%; dark grey, 99 - 80%; light grey, 80 - 60%; and white, 60 - 0% conservation. The NCBI-predicted TSS of
mouse (1), dog (2) and cow (3) Smtnl1 genes as well as the newly defined murine TSS (4) and distance from the promoter to the start codon
(ATG) are indicated. The highly conserved region was further investigated in (B). The Smtnl1 sequence located immediately upstream of the
newly defined TSS (indicated by bold arrow; downstream sequence in bold) was investigated for putative transcription factor binding sites as
indicated. The grey box outlines the mirror repeat sequence (MRS). The dashed line shows the NCBI-derived TSS. The underlined region
highlights the Smtnl1 promoter sequence that strongly enhanced luciferase reporter activity, and “*” indicate 10 nucleotide sections of sequence.
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muscle-specific genes [18], located 190 bp upstream of
the TSS. MyoD shows highest transcriptional activation
when dimerized with another MyoD or other family
members (e.g., Sp1, Mef2 and Pbx) [19,20]. Indeed, possi-
ble non-canonical sites for MyoD as well as Sp1 are
located adjacent to the primary MyoD site in the Smtnl1
p r o m o t e r .T h u s ,r e g u l a t i o no fSmtnl1 expression via
MyoD would explain the robust expression found in ske-
letal muscle when compared to other tissues. We com-
pleted EMSAs with nuclear extracts from mouse skeletal
muscle and DNA probes derived from the MyoD site in
the Smtnl1 promoter (Figure 5A). Gel shifts were sugges-
tive of protein binding to the Smtnl1 MyoD sequence
and could be inhibited with addition of excess unlabelled
probe as a competitive inhibitor. Moreover, EMSAs com-
pleted in the presence of MyoD antibody exhibited a
defined “supershifting” band.
The highest density of putative TFBSs lay within the
sequence GAAGGTGGGGTGGGGTGGAAG of Smtnl1
that forms a 20 bp mirror-repeat sequence (MRS). Mir-
ror repeats are commonly associated with the formation
of an intramolecular triple-helical conformation termed
H-DNA [21,22]. Many promoters, especially those inte-
gral to genes involved in growth regulation, have H-
DNA forming mirror repeats. The Smtnl1 MRS lies
within a region of high transcriptional activation as
determined by luciferase reporter assay, and it is possi-
ble that this region is of paramount importance for
Smtnl1 expression. EMSAs completed with MRS
oligonucleotide probes and nuclear extracts from A7r5
cells demonstrated a single intense band (Figure 5B).
This binding pattern was significantly altered when
nuclear extracts from HEK293 cells were used; in this
case, multiple bands were observed. The results are sug-
gestive of transcription factor binding to the MRS; how-
ever, more in depth investigation will be required to
identify the specific proteins involved.
Other transcription factors are of interest based on
their function and our knowledge of SMTNL1. Putative
binding sites for the nuclear hormone receptor steroido-
genic factor-1 (SF-1) as well as estrogen receptor (ER)
are present. These receptors might be responsible for
the observed differences in Smtnl1 expression during
sexual development in males [3] as well as during preg-
nancy in females [4]. RXRa (retinoid × receptor alpha)
modulates the actions of other hormone receptors and
plays a role in myogenesis. RXRa is also responsible for
the activation of MyoD and deficiency in RXRa causes
defects in skeletal muscle development [23]. Further-
more, RXRa is a binding partner for PPAR (peroxisome
proliferator-activated receptor) transcription factors [24].
In turn, PPARg regulates endurance-exercise induced
fiber type remodeling [25]. Since endurance-exercise
caused up-regulation of Smtnl1,R X R a together with
PPARg might be the responsible factors. Notable is the
absence of a consensus CC-A/T rich-GG (CArG) box,
the binding site for serum response factor (SRF) that is
present in smooth muscle restricted genes [26,27]. This
distinguishes Smtnl1 from the related Smtn genes and is
Figure 5 EMSAs of the putative MyoD-binding and mirror repeat sequence in the murine Smtnl1 promoter.[ g-
32P]-labeled
oligonucleotide probes (3 pmol) were incubated with nuclear extracts isolated from murine skeletal muscle (for MyoD, in A) or A7r5 and
HEK293 cells (for mirror repeat sequence (MRS), in B). In some experiments, 200-fold excess unlabeled competitors were added prior to
incubation with
32P-labeled probes. For supershift analysis, anti-MyoD antibody (1 μg) was introduced with nuclear extracts following the
addition of labeled probe. Results are representative of n = 3 independent experiments.
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tal muscle [3]. Of the numerous transcription factors
predicted to bind to the proximal promoter, several
could be responsible for the adaptive expression of
Smtnl1 after endurance-exercise, pregnancy and sexual
development in smooth and skeletal muscle. This will
be subject to further research.
Conclusions
In the present study, we identified Smtnl1 expression in
all types of smooth muscle tissue (e.g., phasic and tonic;
vascular and visceral) examined, albeit at lower levels
than found in skeletal muscle. Current evidence sup-
ports a key role for SMTNL1 in adaptive responses to
physiological stresses (e.g., pregnancy, exercise and sep-
sis). Therefore, defining key elements of the murine
Smtnl1 gene will enable better understanding of
mechanisms for smooth and skeletal muscle contractile
plasticity in response to physiological stresses.
Methods
RNA samples and cell culture
Mouse total skeletal muscle RNA and mouse total smooth
muscle RNA (from small intestine) were purchased from
Clontech Laboratories (Mountain View, CA). Rat aortic
smooth muscle (A7r5, [ATCC:CRL-1444]), human
embryonic kidney (HEK 293, [ATCC:CRL-1573]) and
rodent fibroblast (Rat 1, [ATCC:CRL-2210]) cells were
maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) in a humidified tissue culture incubator at 37°C with
5% CO2. DMEM and FBS were purchased from Invitrogen
(Carlsbad, CA).
Reverse transcription Polymerase Chain Reaction (RT-PCR)
For all RT-PCR reactions, the ‘standard PCR’ kit from Fer-
mentas (Glen Burnie, MD) was used. All reactions were
carried out using a thermal cycler (Eppendorf Mastercy-
cler; Westbury, NY). Skeletal muscle as well as aorta,
ileum and colonic smooth muscle tissues were removed
from male mice (C57Bl/6) that had been anesthesized and
euthanized according to protocols approved by the Uni-
versity of Calgary Animal Care and Use Committee. Total
RNA and mRNA were extracted using the RNeasy Mini
kit (Qiagen) or Ambion Micro Poly(A) Pure extraction kit,
respectively. First strand cDNA was synthesized using the
Sensiscript RT kit (Qiagen). For the PCR amplification,
Phusion Taq DNA polymerase (New England Biolabs) was
used with the gene-specific primers mSmtnl1-F1,
mSmtnl1-R1, mSmtnl1-nested-F1 and mSmtnl1-nested-
R1. The primer sequences are noted in Supplementary
Table 1. Primers were selected to be unique to Smtnl1
mRNA and did not occur within the transcripts of the
other smoothelin family members. The nested-RT-PCR
reactions were used because they offer increased specificity
and sensitivity. RT-PCR reactions for GAPDH were per-
formed on all RNA samples to verify the integrity of the
RNA.
Northern Blot
Mouse Smtnl1 cDNA (1 - 1038 bp) was radiolabeled
with [a
32P]-dCTP by the random-priming method using
a PrimeIt II Random Primer Labeling kit (Stratagene).
Unincorporated nucleotide was removed with a Nuc-
Away Spin Column (Ambion). A multiple tissue North-
ern blot that contained poly(A)+ RNA from a variety of
human tissues was purchased from Clontech. The poly
(A)+ RNA membrane was prehybridized in ExpressHyb
solution for 30 min at 68°C. Radiolabeled cDNA probe
(~5 × 10
6 cpm/mL) was denatured at 100°C for 2 min
then rapidly chilled on ice. The membrane was incu-
bated with the radiolabeled probe in 5 mL of fresh
ExpressHyb with continuous shaking for 1 h at 68°C.
Following hybridization, the blot was washed for 30 min
at 23°C with 2× SSC (300 mM NaCl, 30 mM Na citrate,
pH 7.0), 0.5% SDS (several washes) and twice for
20 min with 0.1× SSC (15 mM NaCl, 1.5 mM Na
citrate, pH 7.0), 0.1% SDS at 50°C. The membrane was
then subjected to autoradiography.
Rapid Amplification of 5’ cDNA ends (5’-RACE)
The SMART RACE cDNA Amplification kit from Clon-
tech Laboratories was used to amplify 5’-cDNA ends of
mouse smooth and skeletal muscle mRNA. First strand
cDNA synthesis was carried out according to the manu-
facturer’s instructions with mouse total RNAs (Clone-
tech, 1 μg) from intestinal smooth muscle or skeletal
muscle, 5’ CDS primer A, SMART II A oligonucleotide
and TITANIUM Taq DNA polymerase (Advantage 2
PCR System, Clontech). The 5’-RACE PCR reaction was
performed according to the manufacturer’sp r o t o c o l
using Universal Primer A mix (UPM, forward primer)
and one of three Smtnl1 gene specific primers (GSP1-3;
reverse primers). The procedure incorporates an addi-
tional 50 bp to the 5’-end of the PCR product. To verify
the RACE products, nested 5’-RACE PCR was carried
out using nested UPM (NUPM) forward primer and one
of three nested Smtnl1 gene specific reverse primers
(NGSP1, NGSP2). The nested RACE products were
separated on a 1% agarose gel, extracted and cloned into
the TOPO-TA vector (Invitrogen, Carlsbad, CA). All
nested RACE products were sequenced at the University
of Calgary DNA core service.
Ribonuclease protection assay (RPA)
To verify the translation start site (TSS), RPA was per-
formed on murine smooth and skeletal muscle mRNA.
The template for the riboprobe was a chimera of murine
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the Smtnl1 gene (-52 nt to + 160 nt relative to the
NCBI-predicted TSS [Gene ID: 68678]) plus the 5’-end
of exon 2 taken from Smtnl1 (+161 nt to +319 nt [Gen-
Bank: NM_024230.1]) and a T7 primer overhang. The
template was generated using standard PCR methods:
the BAC clone RP23-125A8 (Children’s Hospital Oak-
land Research Institute, Oakland, CA) and primers
RPA-NCS and RPA-NCA were used for the genomic
portion, and the product of the 5’-RACE together with
primers RPA-M1-2 S and RPA-M1-2A was used as the
mRNA part. A second PCR with primers RPA-FR1 and
RPA-RT7 engineered the T7 promoter into the RPA-
template. The riboprobe was synthesized using T7 DNA
dependent RNA transcriptase (New England Biolabs,
Ipswich, MA) according to the manufacturer’si n s t r u c -
tions. To label the riboprobe, biotin-18-UTP/UTP (1:5
ratio) was used in the reaction mix (Invitrogen). For the
RPA, the RPA III kit (Ambion, Austin, TX) was used
with 10 μg mRNA and 100 pg riboprobe. Briefly, murine
mRNA and the riboprobe were hybridized to form
dsRNA (40.5°C, overnight). Then, any remaining single-
stranded mRNA and riboprobe were digested with
RNase. The protected RNA was resolved by denaturing
PAGE and transferred to a SensiBlot nylon membrane
(Fermentas, Glen Burnie, MD). The remaining biotin-
18-UTP-labeled riboprobe was detected using Ambion’s
Brightstar Biodetect kit according to the manufacturer’s
instructions.
Luciferase Assay
A luciferase reporter assay was used to investigate the
putative Smtnl1 promoter sites in the 5’-flanking region.
The Smtnl1 gene and 5’-flanking sequence spanning bp
84662089 to bp 84651332 of mouse chromosome 2 was
obtained from BAC clone RP23-125A8. Different lengths
of Smtnl1 5’-flanking DNA were generated by PCR with
the BAC plasmid as template and cloned into the
pGLuc-Basic vector (New England Biolabs, Ipswich,
MA). The antisense primer utilized for all constructs
engineered a BamHI site at +100 bp downstream of the
transcription start site identified by our previous 5’-
RACE/RPA analysis. Ten different sense primers were
used, adding an EcoRI site for cloning into the pGLuc-
Basic vector. All clones were verified by DNA sequen-
cing. Using Metafectene-Pro (Biontex Laboratories,
München, Germany) and following the manufacturer’s
protocols, we transiently transfected A7r5, HEK 293 or
Rat-1 cells with pGLuc-Basic vectors (5 μg) containing
the various Smtnl1 promoter constructs and pbActb-gal
vector (1 μg). The pbActb-gal vector expresses b-galac-
tosidase under the constitutively active b-actin promoter
and was a kind gift from Dr. J. Cross (University of Cal-
gary). Twenty-four hours before transfection, cells were
plated in 30-mm dishes to produce a density of ~80%
confluence. At 48 hours post-transfection, the media
was assayed for luciferase activity using the Gaussian
Luciferase Assay kit (New England Biolabs) and cell
lysates were assayed for b-galactosidase activity, in quad-
ruplicate samples of three independent experiments. To
account for differences in transfection efficiency, the
luciferase activity was normalized to b-galactosidase
activity and expressed as % change relative to the activ-
ity of empty pGLuc-Basic vector (defined as 100%). As a
positive control, pGLuc-CMV was used in separate
transfections.
Electrophoretic mobility shift assay (EMSA)
DNA binding was assessed by EMSAs with standard
procedures [28] using nuclear extracts prepared from
A7r5 cells or mouse skeletal muscle tissue (hind-limb).
Double-stranded oligonucleotide probes containing the
mirror-repeat (MRS) and putative MyoD binding
sequences located within the Smtnl1 promoter region
were synthesized (sense strands: MRS: 5’-GAAGGTG
GGGTGGGGTGGAAG-3’;M y o D :5 ’-ATTGAAAGA
TGCCACCTGTCAGATCT-3’). Each oligonucleotide
was annealed to its complementary strand, end-labeled
with [g-
32P]-ATP using T4 polynucleotide kinase and
then purified with G-25 Sepharose mini-columns. Bind-
ing reactions were carried out in a mixture containing
1-15 μg nuclear extract proteins in 20 μLo fb i n d i n g
buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, 5% gly-
cerol, pH 7.5). Radiolabeled, double-stranded oligonu-
cleotide probe (3 pmol) was added, and mixtures were
incubated at room temperature for 30 min prior to reso-
lution on 5% non-denaturing polyacrylamide gels (1×
TBE). The gels were then dried, and the radioactive
bands were developed using a Storm phosphoimager
(GE Healthcare). For competition experiments, unla-
beled MyoD or MRS oligonucleotide competitor (200-
fold excess) was added to the reaction mixture before
incubation with the radiolabeled probe. For MyoD
supershift assays, the reaction mixtures were incubated
with 1 μg of anti-MyoD antibody prior to the addition
of radiolabeled probe.
Bioinformatic promoter analysis
The 5’-UTR of the murine Smtnl1 was searched against
mammalian genomes using the BLAST algorithm.
Regions with high alignment score (expectancy value E
<1 0
-10) were aligned using CLUSTALX and GeneDoc
after visual inspection. All mammalian sequences align-
ing to the murine gene (i.e., bp 25704307 to 25703966
of the reverse strand of GenBank: NT-039297.7; 197 bp
upstream of the TSS defined by NCBI) were selected for
further investigation. The sequence identity was
approximately 54%. The region between +38 to -94
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Page 10 of 11relative to the NCBI TSS (-79 to -211 of the newly
defined TSS) was termed highly conserved with an iden-
tity of >72% between all sequences. This region of
highly conserved sequence was analyzed with the
PATCH program for putative transcription factor bind-
ing sites based on the Transfac
® database [16,17].
List of Abbreviations
bp: base pair; cGMP: cyclic-guanidine monophosphate; DMEM: Dulbecco’s
Modified Eagle Medium; EMSA: electrophoretic mobility shift assay; FBS: fetal
bovine serum; MRS: mirror repeat sequence; MyoD: myogenic differentiation-
1; nt: nucleotide; PKA: protein kinase A; PKG: protein kinase G; 5’-RACE: rapid
amplification of 5’ cDNA ends; 3’-RACE: rapid amplification of 3’ ends; RPA:
ribonuclease protection assay; SMTN: smoothelin; SMTNL1: smoothelin-like 1;
SRF: serum response factor; TFBS: transcription factor binding site; TSS:
transcriptional start site; 5’-UTR: 5’ untranslated region.
Acknowledgements
This work was supported by research grants from the Canadian Institutes of
Health Research (CIHR, MOP-72720) and the Heart and Stroke Foundation of
Canada (HSFC). MB was recipient of a HSFC fellowship, and ST was recipient
of an Alberta Innovates - Health Solutions (AIHS) Studentship. JM holds an
AIHS Senior Scholar Award and Canada Research Chair in Smooth Muscle
Pathophysiology.
Authors’ contributions
AU-L carried out MyoD EMSAs and bioinformatic work, interpreted the data
and drafted the manuscript. ST performed RT-PCR for Smtnl1 in mouse
tissues. SM carried out 5’ RACE, RPA and luciferase assay analyses. RW
contributed to the design of 5’-RACE, RPA and nested RT-PCR experiments
as well as the interpretation of the data. MB performed the northern blot.
JM conceived and designed the study, interpreted the data and revised the
manuscript for intellectual content. All authors read and approved the final
manuscript.
Received: 20 October 2010 Accepted: 27 February 2011
Published: 27 February 2011
References
1. Borman MA, MacDonald JA, Haystead TA: Modulation of smooth muscle
contractility by CHASM, a novel member of the smoothelin family of
proteins. FEBS Lett 2004, 573:207-13.
2. Borman MA, Freed TA, Haystead TA, MacDonald JA: The role of the
calponin homology domain of smoothelin-like 1 (SMTNL1) in myosin
phosphatase inhibition and smooth muscle contraction. Mol Cell Biochem
2009, 327:93-100.
3. Wooldridge AA, Fortner CN, Lontay B, Akimoto T, Neppl RL, Facemire C,
Datto MB, Kwon A, McCook E, Li P, Wang S, Thresher RJ, Miller SE,
Perriard JC, Gavin TP, Hickner RC, Coffman TM, Somlyo AV, Yan Z,
Haystead TA: Deletion of the protein kinase A/protein kinase G target
SMTNL1 promotes an exercise-adapted phenotype in vascular smooth
muscle. J Biol Chem 2008, 283:11850-9.
4. Lontay B, Bodoor K, Weitzel DH, Loiselle D, Fortner C, Lengyel S, Zheng D,
Devente J, Hickner R, Haystead TA: Smoothelin Like 1 protein regulates
myosin phosphatase targeting subunit 1 expression during sexual
development and pregnancy. J Biol Chem 2010, 285:29357-29366.
5. Ulke-Lemee A, Ishida H, Borman MA, Valderrama A, Vogel HJ,
MacDonald JA: Tropomyosin-binding properties of the CHASM protein
are dependent upon its calponin homology domain. FEBS Lett 2010,
584:3311-3316.
6. Ishida H, Borman MA, Ostrander J, Vogel HJ, MacDonald JA: Solution
structure of the calponin homology (CH) domain from the smoothelin-
like 1 protein: a unique apocalmodulin-binding mode and the possible
role of the C-terminal type-2 CH-domain in smooth muscle relaxation. J
Biol Chem 2008, 283:20569-78.
7. van der Loop FT, Gabbiani G, Kohnen G, Ramaekers FC, van Eys GJ:
Differentiation of smooth muscle cells in human blood vessels as
defined by smoothelin, a novel marker for the contractile phenotype.
Arterioscler Thromb Vasc Biol 1997, 17:665-71.
8. Georgijevic S, Subramanian Y, Rollins EL, Starovic-Subota O, Tang AC,
Childs SJ: Spatiotemporal expression of smooth muscle markers in
developing zebrafish gut. Dev Dyn 2007, 236:1623-32.
9. Rensen SS, Niessen PM, van Deursen JM, Janssen BJ, Heijman E,
Hermeling E, Meens M, Lie N, Gijbels MJ, Strijkers GJ, Doevendans PA,
Hofker MH, De Mey JG, van Eys GJ: Smoothelin-B deficiency results in
reduced arterial contractility, hypertension, and cardiac hypertrophy in
mice. Circulation 2008, 118:828-36.
10. Niessen P, Rensen S, van Deursen J, De Man J, De Laet A,
Vanderwinden JM, Wedel T, Baker D, Doevendans P, Hofker M, Gijbels M,
van Eys G: Smoothelin-a is essential for functional intestinal smooth
muscle contractility in mice. Gastroenterology 2005, 129:1592-601.
11. Rensen SS, Thijssen VL, De Vries CJ, Doevendans PA, Detera-Wadleigh SD,
Van Eys GJ: Expression of the smoothelin gene is mediated by
alternative promoters. Cardiovasc Res 2002, 55:850-63.
12. Rensen SS, Niessen PM, Long X, Doevendans PA, Miano JM, van Eys GJ:
Contribution of serum response factor and myocardin to transcriptional
regulation of smoothelins. Cardiovasc Res 2006, 70:136-45.
13. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA,
Olson EN: Activation of cardiac gene expression by myocardin, a
transcriptional cofactor for serum response factor. Cell 2001, 105:851-62.
14. Chen J, Kitchen CM, Streb JW, Miano JM: Myocardin: a component of a
molecular switch for smooth muscle differentiation,. J Mol Cell Cardiol
2002, 34:1345-56.
15. Kramer J, Quensel C, Meding J, Cardoso MC, Leonhardt H: Identification
and characterization of novel smoothelin isoforms in vascular smooth
muscle. J Vasc Res 2001, 38:120-32.
16. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I,
Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-
Potapov B, Saxel H, Kel AE, Wingender E: TRANSFAC and its module
TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic
Acids Res 2006, 34:D108-10.
17. Gene-regulation.com. [http://www.gene-regulation.com].
18. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB,
Miller AD: Activation of muscle-specific genes in pigment, nerve, fat,
liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl
Acad Sci USA 1989, 86:5434-8.
19. Weintraub H, Davis R, Lockshon D, Lassar A: MyoD binds cooperatively to
two sites in a target enhancer sequence: occupancy of two sites is
required for activation. Proc Natl Acad Sci USA 1990, 87:5623-7.
20. Knoepfler PS, Bergstrom DA, Uetsuki T, Dac-Korytko I, Sun YH, Wright WE,
Tapscott SJ, Kamps MP: A conserved motif N-terminal to the DNA-binding
domains of myogenic bHLH transcription factors mediates cooperative
DNA binding with pbx-Meis1/Prep1. Nucleic Acids Res 1999, 27:3752-61.
21. Mirkin SM, Lyamichev VI, Drushlyak KN, Dobrynin VN, Filippov SA, Frank-
Kamenetskii MD: DNA H form requires a homopurine-homopyrimidine
mirror repeat. Nature 1987, 330:495-7.
22. Htun H, Dahlberg JE: Single strands, triple strands, and kinks in H-DNA.
Science 1988, 241:1791-6.
23. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L: Retinoid ×
receptors: X-ploring their (patho)physiological functions. Cell Death Differ
2004, 11(Suppl 2):S126-43.
24. Chan LS, Wells RA: Cross-talk between PPARs and the partners of RXR: a
molecular perspective,. PPAR Res 2009, 925309.
25. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J,
Rassoulzadegan M, Grimaldi PA: Peroxisome proliferator-activated
receptor delta controls muscle development and oxidative capability.
FASEB J 2003, 17:2299-301.
26. McDonald OG, Owens GK: Programming smooth muscle plasticity with
chromatin dynamics. Circ Res 2007, 100:1428-1441.
27. Miano JM, Long X, Fujiwara K: Serum response factor: master regulator of
the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol
2007, 292:C70-C81.
28. Noh OJ, Park YH, Chung YW, Kim IY: Transcriptional regulation of
selenoprotein W by MyoD during early skeletal muscle differentiation.
J Biol Chem 2010, 285:40496-40507.
doi:10.1186/1471-2199-12-10
Cite this article as: Ulke-Lemée et al.: Mapping and functional
characterization of the murine Smoothelin-like 1 promoter. BMC
Molecular Biology 2011 12:10.
Ulke-Lemée et al. BMC Molecular Biology 2011, 12:10
http://www.biomedcentral.com/1471-2199/12/10
Page 11 of 11